about
Targeted therapies and immunotherapy in non-small-cell lung cancerLung cancer biomarkers, targeted therapies and clinical assaysHistopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumorsPulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibitionPredicting resistance by selection of signaling pathways.Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
P2860
Q26738986-D94FF9E0-60B0-48A4-A020-3CBE6D4E43C5Q26775396-6E4A8F4B-3535-43D2-910D-E8DB0A3B10E9Q28077504-E6F6B51D-0289-4FCE-A69F-6AF69B36D72AQ34404209-9FF0E962-94A2-40FE-A22E-A61804E9538CQ36265149-8E31656B-B699-4A99-8DB8-774D72971B16Q38390126-3D7B79E5-864B-4DFF-B3E7-E52C378F318BQ39048792-BF9361FA-85D6-4A21-BB0A-AA26B5D9B9E2
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
MET inhibition in lung cancer.
@en
type
label
MET inhibition in lung cancer.
@en
prefLabel
MET inhibition in lung cancer.
@en
P2860
P1476
MET inhibition in lung cancer.
@en
P2093
Silvia Novello
P2860
P356
10.3978/J.ISSN.2218-6751.2012.12.04
P577
2013-02-01T00:00:00Z